

شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلو

بسم الله الرحمن الرحيم





MONA MAGHRABY



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلو



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية التوثيق الإلكترونى والميكروفيلم

جامعة عين شمس التوثيق الإلكتروني والميكروفيلم قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



"Investigation of Adipolin and Subfatin in Osteoarthritis Patients"

A Thesis

Submitted in Partial Fulfillment of the Requirements for the

Master degree

In Pharmaceutical Sciences

(Biochemistry)

By

Basma Hamdi Mahmoud Kamel Hassaneen Sobieh

B. Ph. Sci., Ain Shams University (2013) Demonstrator of Biochemistry, Faculty of Pharmacy, Ain Shams University

Under Supervision of

Prof. Dr. Hala Osman El- Mesallamy

Dean of Faculty of Pharmacy, Sinai University Professor of Biochemistry Faculty of Pharmacy, Ain Shams University

Associate Prof. Dr. Zeiad Mohamed Zakaria

Associate Professor of Orthopedic Surgery Faculty of Medicine Ain Shams University

Dr. Dina Hamada Kassem

Lecturer of Biochemistry Faculty of Pharmacy Ain Shams University



" دراسة الأديبولين و السبفاتين في مرضى خشونة المفاصل"

رسالة مقدمة لاستكمال متطلبات الحصول علي درجة الماجستير في العلوم الصيدلية تخصص (كيمياء حيوية)

إعداد بسمه حمدي محمود كامل حسنين صبيح بكالوريوس العلوم الصيدلية- جامعة عين شمس (٢٠١٣) معيدة بقسم الكيمياء الحيوية- كلية الصيدلة-جامعة عين شمس

تحت إشراف

أ.د/ هالة عثمان المسلمى عميد كلية الصيدلة-جامعة سيناء أستاذ الكيمياء الحيوية كلية الصيدلة-جامعة عين شمس

أ.م.د/ زياد محمد زكريا استاذ مساعد جراحة العظام كلية الطب جامعة عين شمس

د/ دينا حماده قاسم مدرس الكيمياء الحيوية كلية الصيدلة جامعة عين شمس

بســـم الله الرحـــمن الرحــيم
" وَعَلَّمَكَ مَا لَمْ تَكُنْ تَعْلَمُ وَكَانَ فَضْلُ اللهِ
عَلَيْكَ عَظِيمًا"

صدق الله العظيم

سورة النساء-الآية (١١٣)

Contents

Contents

Subjects	
List of Abbreviations	v
List of Figures	viii
List of Tables	X
1. Introduction and Aim of the Work	1
2. Literature Review	4
2.1. Burden of Osteoarthritis	4
2.2. Osteoarthritis Pathophysiology	6
2.3. Osteoarthritis Risk Factors	13
2.4. Obesity-Osteoarthritis interplay (dyslipidaemia-insulin resistance-adipokines linkage)	18
2.5. Adipolin	26
2.6. Subfatin/metrnl	29
2.7. Matrix Metalloproteinase-13 (MMP-13)	32
3. Subjects and Methods	34
3.1. Subjects	34
3.2. Samples	35

Contents

Subjects	Page no.
3.3. Methods	37
3.4. Statistical Analysis	59
4. Results	60
4.1. Study population and clinical data	60
4.2. Assessment of various biochemical parameters related	60
to insulin resistance/sensitivity	
4.3. Lipids Profile	62
4.4. Serum adipolin and subfatin/metrnl levels	64
4.5. Correlation coefficients between serum adipokines and	65
various parameters	
4.6. Association of serum adipolin and subfatin/metrnl	70
levels with OA severity	
4.7. Synovial fluid levels of various investigated biomarkers	73
4.8. Correlation coefficients between synovial fluid	77
biomarkers and various parameters	
4.9. Association of serum/SF adipolin and serum/SF	87
subfatin/metrnl with the OA risk	
4.10. Investigating the effect of obesity (independent of	88
OA) on serum adipolin and subfatin/metrnl levels	
5. Discussion	97
6. Summary and Conclusion	

Contents

Subjects	
8. References	112
9. Appendix	135
10. Arabic Summary	0_1

Publications Related to the Thesis

1) Sobieh BH; Kassem DH; Zakaria ZM; El-Mesallamy HO, "Potential Emerging Roles of the Novel Adipokines Adipolin/CTRP12 and Meteorin-like/METRNL in Obesity-Osteoarthritis Interplay" CYTOKINE. Accepted 2020 November.

Impact Factor=2.952

2) METRNL: A Novel Adipokine with Potential Emerging Role in the Pathogenesis of Osteoarthritis and its Interplay with Obesity. Live Poster in Keystone Symposia (Obesity: From Cell to Patient (EK17)), USA 1 Februay 2021.



METRNL: A Novel Adipokine with Potential Emerging Role in the Pathogenesis of Osteoarthritis

Basma H. Sobieh ^a, Dina H. Kassem ^a, Zeiad M. Zakaria ^b, and Hala O. El-Mesallamy ^{a, c}*

^a Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
^b Orthopedic Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
^c Faculty of Pharmacy, Sinai University, Sinai, Egypt


Background: Osteoarthritis (OA) is one of the ten most disabling diseases worldwide. Obesity is one of the major risk factors for OA. Adipokines are potential candidates that link obesity with OA, and may serve as putative targets for disease-modifying OA drugs, especially for obese patients. Among these adipokines, METRNL is a newly discovered adipokine not only expressed by adipose tissue but also by chondrocytes. Recent studies also suggest its role as an anti-inflammatory adipokine. However, its role in obesity-OA interplay has not been adequately studied.

Methods: Circulating as well as synovial fluid (SF) METRNL and insulin levels, and matrix-metalloproteinase-13 (MMP-13) SF-levels were all measured by ELISA in obese osteoarthritic patients (n=30) and obese non-osteoarthritic subjects (n=25). The severity of the knee articular cartilage damage was evaluated by X-ray radiographs.

Results: Serum METRNL was found to be significantly decreased in OA-patients compared to non-OA-subjects; 31.85 ± 5.09 pg/ml and 51.85 ± 6.29 pg/ml, respectively, p=0.012. Serum METRNL levels were also found to be relatively decreased with the advancing of OA. The higher the serum METRNL levels, the less likelihood to have OA. Furthermore, SF METRNL levels were found to be significantly elevated in OA patients compared to non-OA subjects; 912 [367-1524] and 315 [125-484] pg/ml, respectively, p=0.007

Publications Related to the Thesis

Conclusions: Our results highlight a possibly pivotal role for METRNL in OA pathogenesis. METRNL could provide a new biomarker to for OA state, and disease severity. Different regulatory mechanisms are strongly suggested for regulation of METRNL secretion from different tissues. Conclusively, METRNL is a potential novel therapeutic target for OA.



List of Abbreviations

ABCA-1	Adenosine triphosphate (ATP)-binding cassette transporter-1
ACL	Acute cruciate ligament
ACR	American College of Rheumatology
AGEs	Advanced glycation end products
Akt	Protein kinase B
AMPK	Adenosine monophosphate-activated protein kinase
ANOVA	Analysis of variance
Apo	Apolipoprotein
BAT	Brown adipose tissue
BMI	Body mass index
CI	Confidence intervals
C1qdc2	C1q domain-containing protein
CRP	C-reactive protein
CTRP-12	C1q/tumor necrosis factor-related protein-12
CVD	Cardiovascular disease
ECM	Extracellular matrix
ELISA	Enzyme-Linked Immuno-Sorbent assay
FFA	Free fatty acids
FPG	Fasting plasma glucose
GLM	General linear modelling
HDL-C	High-density lipoprotein-cholesterol
HIF-2α	Hypoxia inducible factor 2α
HOMA-IR	Homeostasis model assessment-insulin resistance
IL	Interleukin
IR	Insulin resistance
JSN	Joint space narrowing
KL	Kellgren-Lawrence

LCAT	Lecithin–cholesterol acyltransferase
LDL-C	Low density lipoprotein cholesterol
LXR	Liver X receptor
MCP-1	Monocyte chemotactic protein-1
Metrnl	Meteorin-like
MMP	Matrix metalloproteinase
MT	Meniscal tear
mtROS	Mitochondrial-ROS
NF-ĸB	Nuclear factor-Kappa B
OA	Osteoarthritis
ORs	Odds ratio
Ox-LDL	Oxidized LDL
PGC-1α	Peroxisome proliferator-activated receptor gamma coactivator-1alpha
PPAR γ	Peroxisome proliferator-activated receptor gamma
QUICKI	Quantitative insulin-sensitivity check index
RA	Rheumatoid arthritis
RAGE	Receptor of AGE
ROS	Reactive oxygen species
Runx2	Runt-related transcription factor-2
SEM	Standard error of mean
SF	Synovial fluid
STAT3	Signal transducer and activator of transcription protein 3
TC	Total cholesterol
T2DM	Type 2 diabetes mellitus
TAG	Triacylglycerols
TIMP	Tissue inhibitor of metalloproteinases
TKA	Total knee arthroplasty
TLR	Toll-like receptor
TNF-α	Tumor necrosis factor-alpha